Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis

Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis

Abstract Background Mucosal sites are hypothesized to play a role in the development of rheumatoid arthritis (RA). Since serum anti-peptidylarginine deiminase (PAD)4 antibodies, including a subset that cross-react with PAD3 (PAD3/4), are specific for RA and associate with severe disease, we sought t...

Full description

Bibliographic Details
Main Authors: M. Kristen Demoruelle, Hong Wang, Ryan L. Davis, Ashley Visser, Johnny Hoang, Jill M. Norris, V. Michael Holers, Kevin D. Deane, Erika Darrah
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Anti-PAD4 antibodies
Lung
Sputum
Saliva
Online Access:https://doi.org/10.1186/s13075-021-02528-5

Internet

https://doi.org/10.1186/s13075-021-02528-5

Similar Items